Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B.
Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for ...
French drugmaker gains access to Covid shot and other tech Sanofi also takes a small stake in Maryland-based company -rte-company state="{"_id":"0000018f-638a-d4b6 ...
The biotech company said it would develop a combination Covid and flu shot with Sanofi as part of a billion-dollar deal.
, opens new tab on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi (SASY.PA) , opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S ...
With flu and COVID hospital admission rates now mirroring each other, Novavax, which lost out in the COVID vaccine race to ...
GXO Opens up New Distribution Hub for Conair <li /> Sinclair Ponders Unloading Stations <li /> AMC Plunges on Q1 Figures <li ...
Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.
Investing.com - Der Kurs der Novavax-Aktie (NASDAQ:NVAX) stieg am Freitag im frühen US-Handel um 114 %. Grund dafür waren nicht die Q1-Zahlen, sondern vor allem ein milliardenschwerer Deal mit ...